Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Hims & Hers’

Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy

Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.

MarketBeat

Hims & Hers Stock Is Trading Lower Tuesday: What's Going On?

Hims Hers Health, Inc. (NYSE:HIMS) stock is trading lower Tuesday after the company reported a second-quarter sales miss on Monday after the market closed.

Benzinga

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Health Stock Tumbles On Q2 Earnings As Revenue Comes Up Short, Company Sees 'Exciting Period Of Growth' Ahead

Hims Hers Health Inc (NYSE:HIMS) reported second-quarter earnings after the market close on Monday. Here’s a rundown of the report.

Benzinga

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

MarketBeat

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Stock Could Rocket To Meme Stock Fame — If Short Sellers Feel The Squeeze

Hims Hers Health, Inc. (NYSE:HIMS) has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally.

Benzinga

What's Going On With Hims & Hers Stock Wednesday?

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

Benzinga

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.

Benzinga

Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback

Hims & Hers stock dipped after Novo Nordisk pulled back its partnership for a weight loss drug distribution, though that may not mean much.

MarketBeat

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know.

Benzinga

Why Hims & Hers Stock Could Be a Multi-Bagger in the Making

Hims & Hers stock keeps giving investors more reasons to buy, and has all the right factors to turn it into a potential multi-bagger investment.

MarketBeat

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

International Business Times UK

Hims Stock Tumbles Down After Abrupt Exit of Novo Nordisk: Here's Everything That Went Wrong

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated Chinese manufacturers not approved or inspected by the FDA.

The Independent UK

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Hims & Hers had partnered with the Danish pharmaceutical giant in April to sell Wegovy

Benzinga

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Hims & Hers Stock: Buy the Dip or Wait It Out?

Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform.

MarketBeat

Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

MarketBeat

Hims & Hers Stock Rises on Fundamentals and Squeeze Potential

Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum.

MarketBeat

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

The Independent UK

You might soon be able to get Wegovy from an online shop — here is where you need to visit

The move comes as Danish drugmaker Novo Nordisk has acted to slash the popular weight loss drug’s price

Barchart

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

MarketBeat

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.